Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) Research & Development (2016 - 2025)

Standard Biotools (LAB) has disclosed Research & Development for 16 consecutive years, with $468000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Research & Development fell 93.26% to $468000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $38.3 million, a 21.94% decrease, with the full-year FY2024 number at $62.4 million, up 140.52% from a year prior.
  • Research & Development was $468000.0 for Q3 2025 at Standard Biotools, down from $6.2 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $20.3 million in Q4 2024 to a low of $468000.0 in Q3 2025.
  • A 5-year average of $9.6 million and a median of $8.5 million in 2021 define the central range for Research & Development.
  • Peak YoY movement for Research & Development: soared 210.83% in 2024, then tumbled 93.26% in 2025.
  • Standard Biotools' Research & Development stood at $8.5 million in 2021, then fell by 13.07% to $7.4 million in 2022, then dropped by 6.95% to $6.9 million in 2023, then skyrocketed by 193.39% to $20.3 million in 2024, then tumbled by 97.69% to $468000.0 in 2025.
  • Per Business Quant, the three most recent readings for LAB's Research & Development are $468000.0 (Q3 2025), $6.2 million (Q2 2025), and $11.3 million (Q1 2025).